Publications by authors named "O Gebara"
Background: While COVID-19 vaccination has been shown to reduce the risk of severe illness, its impact on the occurrence of persistent symptoms in patients with mild Omicron infection remains uncertain. Our objective was to investigate whether COVID-19 vaccination reduces the occurrence of persistent COVID-19-related symptoms 3 months after mild Omicron infection.
Methods: Multicenter prospective cohort study was conducted in Brazil between January 2022 and June 2023 when Omicron was predominant.
Purpose: To assess the effect of antisense therapy to block kallikrein-kinin pathway in COVID-19 patients.
Material And Methods: Randomized, placebo-controlled, double blind, controlled trial enrolling hospitalized COVID-19 patients that required supplementary oxygen to sustain peripheral oxygen saturation. Key exclusion criteria included use of mechanical ventilation or vasopressors, and patients with more than 10 days since symptom onset or more than 48 h of oxygen use.
Predictors of bleeding and thrombotic events among patients admitted to the hospital with COVID-19 and elevated D-dimer: insights from the ACTION randomized clinical trial.
J Thromb Thrombolysis
August 2024
Article Synopsis
- Therapeutic anticoagulation in COVID-19 patients shows mixed outcomes, complicating the selection of suitable patients due to balancing thrombotic and bleeding risks.
- A post-hoc analysis of the ACTION trial examined factors linked to bleeding and thrombotic events, using logistic regression to identify significant variables.
- Key findings included that non-invasive respiratory support related to thrombotic risks, invasive ventilation increased risks for both outcomes, and factors like creatinine levels and a history of coronary disease were important in determining thrombotic risk.
Halofuginone for non-hospitalized adult patients with COVID-19 a multicenter, randomized placebo-controlled phase 2 trial. The HALOS trial.
PLoS One
February 2024
Background: Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent in vitro activity against SARS-CoV-2 virus. The safety and efficacy of halofuginone in Covid-19 patients has not been studied.
Methods: We conducted a phase II, randomized, double-blind, placebo-controlled, dose ranging, safety and tolerability trial of halofuginone in symptomatic (≤ 7 days), mostly vaccinated, non-hospitalized adults with mild to moderate Covid-19.